CLAIMS

What is claimed is:

1. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl –3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Ia or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof



Ia

wherein the substituents are as defined in the following table

Metabolite Code	R1	R2	R3	R4	C9
M1	SG	H	CH_3	OH	C=O
M2	SG	OH	CH_3	H	C=O
M4 & M5	SG	H	CH_3	H	C=O
M6	OCH_3	OH	CH_3	OH	C=O
M7	OH	OCH_3	CH_3	OH	C=O
M8	OH	H	CH_3	OH	C=O
M8A	H	H	CH_3	$(OH)_2$	C=O
M9	H	H	CH_3	H	(CH)OH

M10	H	H	CH_3	OH	C=O
M11	H	H	COOH	H	C=O
M12	H	H	CH_3	OH	C=O
M13	H	H	CH_3	H	C=O

and



5

2. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl –3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Ib or a pharmaceutically acceptable salt, solvate or prodrug thereof



10 Ib

wherein the substituents are as defined in the following table

Metabolite Code	R_1	R_2	R_3	R_4	R_5	R_6
M14	H	H	CH_3	CH_3	H	2O
M15	SG	H	CH_3	CH_3	H	H
M16	H	H	CH_3	CH_3	H	2O

M17	H	H	CH_3	CH_3	OH	H
M18	H	OH	CH_3	CH_3	OH	H
M19	H	H	CH_3	CH_3	OH	H
M20	H	H				H
M21	H	H				H
M22	H	H	CH_3	COOH	H	H
M23	H	H	CH_3	CH_3	OH	H
M24	H	H	COOH	CH_3	H	H

and

SG= 

wherein the side chains on M20 and M21 are as shown below:

M20	
M21	

3. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl –3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Ic or a pharmaceutically acceptable salt, solvate or prodrug thereof



1c

wherein the substituents are as defined in the following table:

Metabolite Code	R_1	R_2	R_3	R_4	C9	C13
M9	CH_3	H	$CO(CH_3)$	$CO(OCH_3)$	(CH)OH	(CH)OH
M10	CH_3	OH	$CO(CH_3)$	$CO(OCH_3)$	C=O	(CH)OH
M10A	CH_3	H	H	$CO(OCH_3)$	C=O	(CH)OH
M11	COOH	H	$CO(CH_3)$	$CO(OCH_3)$	C=O	(CH)OH
M10B	CH_3	OH	$CO(CH_3)$	$CO(OCH_3)$	C=O	(CH)OH
M10C	CH_3	H	$CO(CH_2OH)$	$CO(OCH_3)$	C=O	(CH)OH
M12	CH_3	OH	$CO(CH_3)$	$CO(OCH_3)$	C=O	(CH)OH
M13	CH_3	H	$CO(CH_3)$	$CO(OCH_3)$	C=O	(CH)OH
M13A	CH_3	H	H	$CO(OCH_3)$	C=O	C=O
M13B	CH_3	OH	$CO(CH_3)$	H	C=O	(CH)OH
M13C	CH_3	H	$CO(CH_3)$	$CO(OCH_3)$	C=O	(CH)OH
M13D	CH_3	H	$CO(CH_3)$	$CO(OCH_3)$	C=O	C=O

4. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl –3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Id or a pharmaceutically acceptable salt, solvate or prodrug thereof



1d

wherein the substituents are as defined in the following table:

Metabolite Code	R_1	R_2	R_3	R_4	R_5
M15B	$CO(CH_3)$	CH_2OH or COOH	COOH or CH_2OH	H	H
M17	$CO(CH_3)$	CH_3	CH_3	H	OH
M18B	H	CH_3	COOH	H	H
M19	$CO(CH_3)$	CH_3	CH_3	H	OH
M19A	H	COOH	CH_3	H	H
M22	$CO(CH_3)$	CH_3	COOH	H	H
M23	$CO(CH_3)$	CH_3	CH_3	H	OH
M24	$CO(CH_3)$	COOH or CH_3	CH_3 or COOH	H	H
M23A	$CO(CH_3)$	CH_3	CH_3	OH or H	H or OH
M23B	$CO(CH_3)$	CH_3	CH_3	OH	H
M23C	$CO(CH_3)$	CH_3	CH_3	OH or H	H or OH
M26	H	CH_3	CH_3	H	H
M23D	$CO(CH_3)$	CH_3	CH_3	OH	H

M27	$CO(CH_3)$	CH_3	CH_3	H	H

5. A pharmaceutical composition comprising a metabolite according to Claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

6. A pharmaceutical composition comprising a metabolite according to Claim 2 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

7. A pharmaceutical composition comprising a metabolite according to Claim 3 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

8. A pharmaceutical composition comprising a metabolite according to Claim 4 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

9. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 1.

10. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 2.

11. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 3.

12. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 4.